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Abstract 
Background and Aims: The possible contribution of iron to cardiovascular complications of 
type 2 diabetes (T2D) has been scarcely investigated. We aimed to study whether serum 
ferritin is linked to prevalent/incident cardiovascular disease (CVD) in T2D. 
 
Methods: The prevalence of coronary heart disease (CHD), cerebrovascular disease 
(CEVD) and CVD were evaluated in the SIDIAP study (n=38,617) and prevalence and 7 
year incidence were analysed in the Edinburgh Type 2 Diabetes Study (ET2DS)(n=821). 
Logistic and Cox regressions were used to describe associations between serum ferritin and 
the CVD adjusting for confounding variables.  
 
Results: Increase of 1 SD unit in log-ferritin was associated with lower CVD prevalence in 
fully-adjusted models [ET2DS Odds ratio (OR) 95% confidence interval (CI): 0.81(0.68-0.96), 
P=0.018; SIDIAP study: 0.91(0.88-0.94), P<0.001). In ET2DS, ferritin in the highest (vs. the 
lowest) quintile was associated with lower incidence of CVD [fully adjusted HR 95% CI: 
0.46(0.26-0.83), P=0.010]. This association persisted after removing subjects with CVD at 
baseline (n=536) [HR 95% CI: 0.34 (0.14-0.81), P=0.016].  
 
Conclusions: Low iron status was associated with CVD risk in T2D. This pattern was 
consistent in populations at different cardiovascular risk. Low iron status seems to be 
harmful for cardiovascular health in T2D and it may be a target for intervention.  
 
Keywords: ferritin,  cardiovascular disease, type 2 diabetes
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Introduction 
A positive association between increased body iron stores, estimated as serum ferritin, and 
incidence of type 2 diabetes (T2D) has been consistently reported (1, 2)]. In the general 
population, iron has been hypothesised to promote the development of the atherosclerotic 
plaque through increased oxidative stress as a consequence of the pro-oxidant properties of 
iron (3)]. Although iron excess has been the most reported iron imbalance associated with 
insulin resistance and development of diabetes and metabolic syndrome in general 
populations, its association with cardiovascular disease is still controversial.  Iron excess 
reflected by high ferritin levels  was positively associated with incident coronary heart  
disease in Finnish men but subsequent studies have failed to replicate this association (4)].  
 
On the other hand, a significant negative association between transferrin saturation and 
development coronary artery disease or myocardial infarction has been recently identified in 
the general population in a recent meta-analysis. Puzzlingly, no significant association was 
found with serum ferritin (5)]. Importantly, a recent Mendelian randomisation study reported 
that genetic markers related to systemic high iron status (rs1800562 and rs1799945 in the 
HFE gene and rs855791 in TMPRSS6 gene) reduced the risk of coronary heart disease 
(CHD) in the general population(6)].  
 
Little attention has been paid to the possible involvement of iron in chronic diabetic 
complications. Iron imbalance could potentiate the risk for cardiovascular outcomes in 
people who already have T2D. So far, only one cross-sectional study of 424 people has 
tested this hypothesis. The authors reported an apparently paradoxical decreased 
prevalence of macroangiopathy in men with T2D and increased serum ferritin levels but 
adjustment for covariates was not performed (7)].  
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In the light of the above, we aimed to characterise the association between serum ferritin 
with (CHD) and cerebrovascular disease (CEVD) with adjustment for covariates in two 
different cohorts of people with type 2 diabetes, one from Scotland-UK and other from 
Catalonia-Spain using both cross-sectional and prospective study designs. This multi-cohort 
approach was used to evaluate whether any association was consistent in different 
populations even despite different cardiovascular risk, which is higher in British (8, 9)] than in 
Mediterranean populations (10)].  
 
 
Patients and Methods 
 
Study population 
ET2DS 
Methods of the Edinburgh Type 2 Diabetes Study (ET2DS) have been described in full 
previously (11)]. The ET2DS is an ongoing prospective study with available data for eight 
years follow-up. Briefly patients with type 2 diabetes aged 60–75 years were selected at 
random from the Lothian Diabetes Register, a comprehensive register of patients with 
diabetes living in Lothian, Scotland, UK, which was established in 2001. Baseline attendees 
(n=1,066) have previously been shown to be representative of all those randomly selected to 
participate (n=5,454), and therefore representative of the target population of older people 
with type 2 diabetes living in the general population. There was a liver assessment clinic 
attended by 939 participants at year 1, and ferritin levels were measured in 876 of those 
participants. Therefore year 1 was used as baseline for this study and follow-up for the 
present analysis was of seven years. Of the 876 subjects with ferritin measurements we 
excluded 55 individuals with missing values for covariates leaving a remaining final sample 
of 821 participants. 
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SIDIAP study – Primary Care Centers in Catalonia 
This cross-sectional study is based on the SIDIAP system which a computerized database 
containing anonymized patient records for the 5.8 million people registered with a GP in the 
Catalan Health Institute. The SIDIAP database includes data from  a software called ECAP 
used by general practitioners to record clinical information on patients (demographics, 
consultations with GPs, diagnoses, clinical variables, prescriptions, and referrals), laboratory 
test results, and medications obtained from the pharmacists (provided by the CatSalut 
database) (12)]. Methods of SIDIAP study have been described in full previously (12, 13)]. 
Of 318020 individuals with T2D aged 30-99 years registered in the SIDIAP database in 
2011, 62002 had at least one measurement of ferritin during this year. The final sample for 
the analysis was composed of 38617 individuals after excluding cases with missing values 
for covariates.  
 
CVD events  
The ET2DS has data on prevalent and incident CVD events, and the SIDIAP study on 
prevalent CVD only. The ET2DS has had eight years follow-up. Prevalent and incident 
events up to year 4 were collected using a combination of record linkage (hospital discharge 
and death certification data), repeat self-report and GP questionnaires, repeat ECG and 
inspection of clinical notes. Incident events between year 4 and year 8 were collected using 
a combination of record linkage and inspection of clinical notes. Data linkage was 
undertaken, via the National Health Service National Services Scotland, to Scottish Morbidity 
Record (SMR01) general and acute inpatient discharge records using ICD-10 (www.who.int/
classifications/icd/en/) (and related ICD-9 [www.icd9data.com/2007/Volume1]) codes. CVD 
cases of the SIDIAP study were defined on the basis of record linkage. 
 
Ischemic heart disease or coronary heart disease (CHD) was in terms of angina or 
myocardial infarction (ICD-10 codes I20, I21, I22, I23). The SIDIAP study also included the 
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category of “other acute ischaemic heart disease” (ICD-124). Cerebrovascular disease 
(CEVD) was in terms of stroke (ICD-10 codes I63, I64) and transient ischaemic attack (TIA) 
(ICD-10 code G45). The ET2DS also included ICD-10 code 161 for intracerebral 
hemorrhage, and the SIDIAP study also considered the ICD-10 code G46 on vascular 
syndromes of brain in cerebrovascular diseases. In the ET2DS fatal cases of myocardial 
infarction and stroke were according to have the respective ICD-10 codes as primary cause 
of death. The ET2DS also used inspection of clinical notes to confirm CVD cases (prevalent 
or incident) if non-primary ICD-10 code for CHD or CEVD was reported, except in the cases 
of angina. 
 
Clinical and biochemical variables 
The SIDIAP included similar clinical and biochemical variables than the ET2DS, with 
exception of fibrinogen, CRP, and transaminases levels, and estimation of liver disease 
which were available in the ET2DS only. In the SIDIAP study white blood cells count was 
used as a measure of inflammation, and triglyceride levels was also available. 
Measurements of clinical variables of weight, height , blood pressure, estimation of liver 
disease and biomarkers [haemoglobin levels, HbA1c, fasting glucose, HDL-cholesterol, total 
cholesterol, triglycerides, white blood cells count, C reactive protein (CRP), fibrinogen, 
transferases levels and estimated glomerular filtration rate (eGFR] were performed as 
described elsewhere for both studies (13-15)]. In both studies ferritin levels were measured 
by immunoturbidimetry (intra- and interassay coefficients of variation <8). 
 
Data analyses for the ET2DS and SIDIAP study 
Study variables were described as median (interquartile ranges) or proportions if categorical. 
Ferritin levels were described using Z scores of logarithm of ferritin values (continuous 
variable) and also as sex-specific quintiles (categorical variable), in order to evaluate linear 
and non-linear relationships. Z score of log-ferritin was chosen instead of ferritin or log-
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ferritin alone to provide information about changes in risk of the outcomes by increasing 
standard deviations of the iron marker. In the case of quintiles of ferritin, since iron overload 
has been the most commonly reported for cardio-metabolic risk in general population, the 
first quintile was used as reference. Baseline cross-sectional associations between ferritin 
and prevalent cardiovascular diseases were tested by using logistic regression. Longitudinal 
associations were evaluated by using Cox regression, and proportional hazards assumption 
was tested by Schoenfedl residuals test and graphical method. For this analysis the years of 
follow-up were calculated from date of attendance at year 1 (baseline of this study) to the 
first of date of CVD event, death or end of December 2014. For individuals who developed 
both CHD and CEVD, the years of follow-up for incident or recurrent CVD were derived 
using the date of the first event. We conducted logistic and Cox regressions creating 
adjustment models with covariates associated with the outcomes in univariate analyses at a 
level of statistical significance <0.1 and which remained statistically significant with P< 0.05 
in the multivariate regression using a backward elimination approach. The covariates tested 
were chosen on the basis of possible influence in cardiovascular risk and/or serum ferritin 
levels, and were: age (at baseline ET2DS), sex, duration of diabetes, use of specific anti-
hyperglycaemic agents, treatment with insulin, lipid-lowering drugs, blood pressure-lowering 
drugs, smoking(ever/never), alcohol consumption (ever/never), body mass index (BMI), 
systolic blood pressure (SBP), diastolic blood pressure (DBP), HbA1c, fasting glucose, HDL-
cholesterol, total cholesterol, C reactive protein (CRP), fibrinogen, liver enzymes, liver 
disease, estimated glomerular filtration rate (eGFR), haemoglobin levels, and antiplatelet 
drugs. Anaemia as haemoglobin levels < 13 g/dL in men/ <12 g/dL in women(16), was 
alternatively tested instead of haemoglobin levels. The cross-sectional analysis in the 
SIDIAP study included the above covariates except fibrinogen, CRP, fasting glucose and 
transaminases levels, but included white blood cells count (WBC) and triglycerides levels.  
Additionally we performed the regressions adjusting for all the covariates of potential 
influence in models of increasing complexity, regardless of statistical significant association 
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with the outcomes, and these findings are presented in the supplementary file. More details 
about the methodology for statistical analyses are described in the supplementary file. A p 
value <0.05 was set as statistically significant. All the analyses were performed using 
STATA software 14.0. 
 
Results 
 
Cross-sectional associations  
As expected, serum ferritin levels were significantly lower in women than in men in both the 
ET2DS [median, interquartile range 56 (23-100) µg/L vs. 96.5 (45.5-179.2) µg/L and SIDIAP 
study [46.1 (21-101) µg/L vs. 97.0 (39.0-208) µg/L (P<0.0001). In both studies, CVD was 
more prevalent in men than in women [In ET2DS: CVD 41% vs. 28.1% (P<0.001), CHD 
36.3% vs. 24.3% (P<0.001), and CEVD 10.9 vs. 6.3% (P=0.018); In SIDIAP study:  CVD 
28.5 % v. 16.3% (P<0.001), CHD 22.0 % v. 11.4% (P<0.001), and CEVD 9.1 v. 5.9 % 
(P<0.001)]. Serum ferritin levels were decreased with longer duration of diabetes in the 
ET2DS and the SIDIAP study, Figure 1 in the Supplementary file. 
 
 
SIDIAP study 
Study variables of the 38,617 patients with T2D are described by sex-specific quintiles of 
ferritin in (Table 1). The proportion of subjects reporting alcohol intake increased across the 
quintiles of serum ferritin. In this large population, the proportion of individuals taking oral 
anti-hypoglycaemic and antiplatelet drugs decreased across quintiles of ferritin. The same 
occurred with values of HbA1C, SBP and eGFR, and with the number of cases with insulin, 
antihypertensive, and lipid-lowering treatments. There were dose-response relationships 
between serum ferritin concentration, haemoglobin levels, serum total cholesterol and 
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triglycerides level. Cases of CHD, CEVD and CVD, were increased in the lower quintiles of 
ferritin (Table 1). 
 
In subjects from the SIDIAP study, ferritin as continuous variable or as quintiles was 
significantly inversely related to the opportunity of having CVD (Table 2). 
 
ET2DS cohort 
Study variables at baseline are described by sex-specific quintiles of ferritin in Table 3. 
Values of haemoglobin levels, blood glucose, CRP, transaminases, and DBP increased 
across quintiles of ferritin. As in the SIDIAP study, there were higher proportions of 
individuals reporting alcohol consumption across increasing levels of ferritin, and use of oral 
anti-hyperglycemiant drugs and aspirin decreased across increasing levels of ferritin. CVD 
prevalence tended to decrease across ferritin quintiles (P for trend=0.092) (Table 3).   
 
Table 4 shows cross-sectional associations of ferritin with prevalent cardiovascular disease. 
In terms of ferritin as quintiles, comparing the lowest v. highest category, there was an 
inverse association of ferritin levels with CVD marginally significant [Odds ratio (OR) 95% 
confidence interval (95%CI) : 0.62(0.37-1.04) ; P=0.073] after adjustments. When ferritin 
levels as a continuous variable were introduced in the same adjustment model, the inverse 
association with CVD became more evident [OR 95%CI : 0.81(0.68-0.96); P= 0.018].  
 
Comparisons of the study variables between the SIDIAP study and the ET2DS are described 
and shown in the online Supplementary file and Table 1 in the Supplementary file, 
respectively.  
 
Longitudinal findings (ET2DS) 
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After a mean follow-up of 6.1 ± 1.7 years [median 6.7, interquartile range 6.3-6.9] the 
number (proportion) of people with incident or recurrent outcomes were 123 (15%) for either 
CHD or CEVD, 78 (9.5%) for CHD, and 54 (6.6%) for CEVD.  Nine people developed both 
types of events during the follow-up. When considering participants without disease at 
baseline (n=536) with a mean follow-up of 6.2 ± 1.5 years [median 6.7 (6.4-7.0)], there were 
60 patients (11.2%) with incident CVD, 38(7.1%) with incident CHD, and 25(4.7%) with 
incident CEVD. There was no significant difference by sex in proportion of incident or 
recurrent cases for CVD (57 men, 66 women), CHD (34 men, 38 women) or CEVD (32 men, 
22 women) during follow-up. There were 132/821 (16.1%) deaths during the follow-up, with 
26/132 (19.6%) cases due to CVD, of which 19 were attributable to CHD. 
 
Hazard ratios (HR) and 95% confidence intervals (CI) for cardiovascular disease are shown 
in Table 5 according to quintiles of ferritin. In a full-adjusted model that included CVD at 
baseline, when comparing the extreme quintiles, ferritin was inversely associated with 
development of CVD (HR 95% CI 0.46[0.26-0.83] P=0.010]. When restricting the analyses to 
536 people without prevalent cardiovascular disease at baseline, the longitudinal inverse 
associations between ferritin levels and CVD persisted [HR 95% CI 0.34(0.14-0.81); 
P=0.016] (Table 5).  
 
 
The findings of inverse association between serum ferritin and CVD previously described 
were also obtained in adjustment models of increasing complexity with all the covariates 
[ET2DS HR(95%CI)= 0.50(0.27-0.94) P=0.031; SIDIAP  OR(95%CI)= 0.61 (0.55-0.66) 
P<0.001] (Tables 2-7 in the supplementary file). Specific associations of serum ferritin with 
CHD and CEVD are also shown in the above tables of the supplementary file. These 
associations were consistent with the associations with CVD, except ferritin-CEVD in the 
ET2DS, presumably due to lower statistical power.  
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Iron deficiency was associated with CHD and CVD in the SIDIAP study and with incident 
CHD in women of the ET2DS (more details in Supplementary file). Comparisons between 
the included and excluded subjects of the SIDIAP study (Table 8 in the Supplementary file), 
and additional adjustments and sensitivity analyses mentioned in the data analysis section 
(Supplementary file), are described in the Supplementary file.  
 
 
Discussion 
 
We have described independent inverse cross-sectional and prospective association 
between ferritin levels and cardiovascular disease in representative samples of older people 
with type 2 diabetes from Catalonia-Spain and from Scotland. The multivariate adjusted 
estimates  are similar to the previous unadjusted cross-sectional observations by Hermans 
et al. (7)], and suggests that the inverse association between ferritin levels and incident or 
recurrent CVD in people with type 2 diabetes is also observed in larger samples,  in a 
prospective design, and in populations at different cardiovascular risk.  
 
Low iron status or iron deficiency could explain higher cardiovascular risk in the subjects 
affected by diabetes of our study. Besides the cross-sectional evaluation by Hermans et al. 
(7)], there are few other studies to which we can compare our findings in T2D.  Iron depletion 
by phlebotomy in people with diabetes and peripheral arterial disease (n=636, controls 641) 
did not decrease all-cause mortality or incidence of cardiovascular events (17)].  In other 
study, both low and high ferritin levels, and high soluble transferrin receptors levels were 
associated with 5-year all-cause mortality rate in 287 people with diabetes and stable 
coronary artery disease (18)]. Current findings are supported by recent studies in the general 
population describing inverse associations between iron markers and development of CHD 
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in meta-analyses of existing studies (5)] and in a mendelian randomization approach (6)]. 
However, the underlying mechanisms are still unclear. Meanwhile, the ferritin-CEVD 
association may require a relatively high statistical power, since this was only observed in 
the large population of the SIDIAP study. 
 
The inverse association between iron status and CVD could also suggest that high iron 
status may be a protective factor against CVD in people with diabetes. Hermans et al. 
claimed this hypothesis by highlighting lesser known pleiotropic anti-oxidant properties of the 
ferritin protein itself potentially acting as a compensatory response to inflammation in type 2 
diabetes (7)]. Findings in murine models of oxidative stress-induced synthesis of iron 
proteins in diverse cell lines support this idea since inflammation is linked to increased 
oxidative stress (19)].  However, in our study the association was unaffected when adjusting 
for inflammatory markers such as CRP or fibrinogen levels.  
 
Our findings may also be associated to pleiotropic effects of ferritin on blood vessel 
formation. An in vitro study showed that ferritin stimulates proliferation of endothelial cells via 
inactivation the HKa, which is a potent angiogenesis inhibitor (20)]. Therefore a higher iron 
status in T2D, in terms of high ferritin, might preserve integrity of vascular tissue decreasing 
the risk for cardiovascular injuries.  
 
Our finding that high iron status appears to be a protective factor for cardiometabolic risk in 
T2D could be also related to the course of T2D rather than direct causal beneficial effects of 
ferritin. Systemic metabolic alterations triggered by T2D can encompass several regulatory 
pathways of iron metabolism affecting ferritin levels, circulating iron and ultimately the 
cardiovascular risk attributable to iron. A recent study in mouse and in-vitro models 
confirmed that starvation promotes raising of serum ferritin levels, hepatic and splenic iron 
retention and decreased serum iron via gluconeogenesis,  a persistently active pathway in 
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T2D, with subsequent increasing levels of the hormone hepcidin (21)]. In other words, high 
ferritin levels in T2D could reflect circulatory iron depletion which would avoid pro-oxidant 
iron effects in vascular function.   It is also likely that type 2 diabetes influences iron proteins 
through other mechanisms and/or that there is residual confounding from factors not 
measured in the present study. 
 
To the best of our knowledge this is the first longitudinal study and large cross-sectional 
study evaluating body iron stores and cardiovascular complications in T2D. Additional 
strengths were the use of large and representative samples of people with T2D and a broad 
set of covariates to verify an independent association. 
 
CRP, haemoglobin and fibrinogen levels were measured at the original baseline of the 
ET2DS, one year before ferritin was measured. However, CRP and haemoglobin levels were 
related in a dose-response manner to ferritin quintiles, which is in line with the positive 
associations between these markers that have been observed in diverse populations(22, 
23)], although with variable and modest strength in the case of CRP (24-26)].  
 
There were slight differences in definitions of CHD and CEVD in the ET2DS and the SIDIAP 
study due to predetermined ways of establishing variables of disease in each study. This 
may have biased findings on the ferritin-CEVD association which was significant in the 
SIDIAP study only, but as mentioned previously, this discrepancy would be more related to 
statistical power. On the other hand, the ferritin-CHD association was consistent in both 
studies. There is a possible selection bias in the SIDIAP cohort because serum ferritin 
measurement was more probably performed in subjects suspected of having iron disorders, 
and excluded individuals had different characteristics from those included.  However, these 
issues may not have had substantial influence since adjustment for anaemia did not affect 
the significance of the associations, and the association between ferritin and CVD was 
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present in included and excluded individuals. There was also difference in the age ranges of 
the studies evaluated, but our sensitivity analysis using identical ranges did not alter our 
conclusions.  It will be interesting to study whether the observations obtained in this study 
stand only for T2D patients or extend to other conditions in which a chronic oxidative stress 
state is prominent. 
 
Conclusion 
 
Low iron status seems to be harmful for cardiovascular health in T2D. Although the 
underlying mechanisms for this association remain unclear and further studies are required, 
subclinical/clinical inflammation, body mass index, concomitant treatment, cardiovascular 
risk factors, anaemia, aspirin intake and duration of diabetes, do not appear to be primary 
explanatory variables. It is also plausible that residual confounding could contribute to the 
association.  
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Table 1. Characteristics of people with type 2 diabetes by sex-specific quintiles of ferritin level in the SIDIAP study(n=38617) 
 Ferritin (µg/L)  
 Q1 (n=7712) 
 
Q2(n=7740) 
 
Q3(n=7724) 
 
Q4(n=7732) 
 
Q5(n=7709) 
 
P for trend 
Sex Male/Female n 3283/4429 3275/4465 3296/4428 3290/4442 3279/4430  
Ferritin levels range by sex 
(µg/L) 
      
Men (n=14757) 3.0-31.3 31.4-69.9 70.0-131.1 131.2-244 244.1-3507.8  
Women (n=19847) 1.0-17.7 17.8-34.0 34.1-62.0 62.1-121 121.1-3682.1  
Variables       
Age (years) 74 (65-79) 75 (66-80) 74 (65-80) 72 (63-80) 71 (63-79) <0.001 
Duration of diabetes (years) 7.8 (5.4-11.5) 7.7 (5.2-11.1) 7.5 (4.6-10.8) 7 (3.6-9.9) 6.2 (2.6-8.8) <0.001 
Ferritin (µg/L)  13.3 (9.9-17) 31.6 (23.9-44.6) 57.6 (44.6-92) 110.1 (82-168.2) 273 (178.3-
390.9) 
<0.001 
Haemoglobin (g/dL) 12.0(11.0-13.0) 12.6(11.7-13.7) 12.9(11.9-14.0) 13.2(12.1-14.3) 13.3(12.0-14.5) <0.001 
HbA1C (%) 7.1 (6.5-8) 7 (6.4-7.9) 6.9 (6.3-7.8) 6.8 (6.3-7.7) 6.8 (6.2-7.6) <0.001 
White blood cells count (cells/µL) 7.2 (6-8.5) 7.2 (6-8.5) 7.2 (6-8.6) 7.1 (6-8.5) 7.2 (6-8.6) 0.364 
Smoking [ever]n(%) 2463 (31.9) 2202 (28.4)  2220 (28.7) 2274 (29.4) 2328 (30.2) <0.001 
Alcohol consumption [ever] n(%)  1338 (17.3) 1374 (17.8) 1567 (20.3)  1706 (22.1) 1897 (24.6)  <0.001 
BMI (Kg/mts2)  29.4 (26.5-33) 29.4 (26.3-32.8) 29.3 (26.4-32.9) 29.3 (26.4-32.9) 29.3 (26.3-32.9) 0.217 
SBP mmHg 135 (125-142) 134 (125-141) 134 (125-141) 135 (125-141) 134 (125-140) <0.001 
DBP mmHg 73 (67-80) 73 (66-80) 74 (67-80) 73 (68-80) 75 (68-80) <0.001 
Total cholesterol mg/dl 4.52 (3.93-5.14) 4.57 (3.98-5.24) 4.62 (4.0-5.24) 4.68 (4.06-5.35) 4.73 (4.0-5.43) <0.001 
HDL-cholesterol mg/dl  1.21 (1.03-1.44) 1.21 (1.03-1.44) 1.24 (1.03-1.47) 1.24 (1.03-1.47) 1.21 (1.03-1.44) 0.403 
Triglycerides mg/dl  1.43 (1.06-1.97) 1.43 (1.06-1.97) 1.41(1.03-1.96) 1.42 (1.05-1.97) 1.51 (1.10-2.10) <0.001 
eGFR, mL/min/1.73 m2 60 (58.5-60) 60 (52.9-60) 60 (52.3-60) 60 (53.5-60) 60 (53.4-60) <0.001* 
Antiplatelet drugs n(%) 3980(51.6) 3814(49.3) 3500(45.3) 3104(40.1) 2527(32.8) <0.001 
Oral hypoglycaemic drugs n(%)  6503 (84.3) 6185 (79.9) 5952 (77.1) 5575 (72.1) 5116 (66.4) <0.001 
Antihypertensive drugs n(%) 6312 (81.8) 6506 (84.1) 6284 (81.4) 6066 (78.5) 5896 (76.5) <0.001 
Insulin therapy n(%) 2026 (26.3) 1997 (25.8) 1808 (23.4) 1606 (20.8) 1378 (17.9) <0.001 
Lipid-lowering drugs n(%) 4961 (64.3) 4869 (62.9) 4944 (64) 4669 (60.4) 4327 (56.1) <0.001 
CHD n(%) 1504 (19.5) 1429 (18.5) 1296 (16.8) 1034 (134) 880 (11.4) <0.001 
CEVD n(%) 668 (8.7) 626 (8.1) 572 (7.4) 511 (6.6) 435 (5.6) <0.001 
CVD n(%) 2008 (26) 1894 (24.5) 1723 (22.3) 1441 (18.6) 1220 (15.8) <0.001 
Data are median (interquartile range) or prevalence (95% CI). P for trend across quintiles by Jonckheere-Terpstra Test (continuous variables) 
and 2 tests (categorical variables). Q, quintile. CI, confidence interval. HDL-C, HDL cholesterol. BMI, body mass index. eGFR, estimate 
glomerular filtration rate. HbA1C, glycosylated haemoglobin. SBP, systolic blood pressure. DBP, diastolic blood pressure.*Positive trend is more 
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evident in terms of rank values. 
 
 
Table 2. Multivariate model* explaining prevalent cardiovascular disease in the SIDIAP study 
 OR 95%CI P value 
Ferritin 
(Z score of log-ferritin) 
 
0.91(0.88-0.94) 
 
P<0.001 
Ferritin (µg/L)   
Quintile 1 1.0(Reference)  
Quintile 2 0.91(0.84-0.99) 0.036 
Quintile 3 0.87(0.80-0.95) 0.002 
Quintile 4 0.77(0.70-0.84) <0.001 
Quintile 5 0.72(0.65-0.79) <0.001 
   
Age (years) 1.02(1.02-1.03) <0.001 
Sex Male/Female n 1.65(1.54-1.77) <0.001 
Smoking [ever] 1.07(1.03-1.11) <0.001 
Alcohol consumption [ever]  0.94(0.89-0.99) 0.020 
BMI (Kg/mts2)  0.98(0.98-0.99) <0.001 
SBP mmHg 0.99(0.99-0.99) 0.032 
DBP mmHg 0.98(0.98-0.99) <0.001 
HDL-cholesterol mg/dL 0.98(0.97-0.98) <0.001 
LDL-cholesterol mg/dL 0.99(0.99-0.99) <0.001 
Triglycerides mg/dl  0.99(0.99-0.99) 0.014 
eGFR, mL/min/1.73 m2 0.99(0.99-0.99) 0.014 
Oral hypoglycaemic drugs  0.65(1.04-1.19) <0.001 
Antihypertensive treatment  2.04(1.84-2.26) <0.001 
Insulin therapy  1.11(1.04-1.19) 0.001 
Lipid-lowering treatment 2.09(I1.95-2.23) <0.001 
Antiplatelet treatment  5.28(4.96-5.63) <0.001 
* Model on the basis of variables selected from a previous univariate analysis (P<0.1) and which remained 
significant in the multivariate model after a backward elimination approach (P<0.05).  
The variables  tested in the univariate analysis were the following: age, sex, duration of diabetes, use of 
specific anti-hyperglycaemic agents, treatment with insulin, lipid-lowering drugs, blood pressure-lowering 
drugs, smoking(ever/never), alcohol consumption (ever/never), body mass index (BMI), systolic blood 
pressure (SBP), diastolic blood pressure (DBP), HbA1c, triglycerides, HDL-cholesterol, LDL-cholesterol, 
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total cholesterol, white blood cells count, estimated glomerular filtration rate (eGFR), haemoglobin levels, 
and antiplatelet drugs. Anaemia was alternatively tested instead of haemoglobin levels.  
CI, confidence interval. BMI, body mass index. SBP, systolic blood pressure. DBP, diastolic blood 
pressure. CRP, C reactive protein. GGT, gamma-glutamyl transpeptidase. ALT, Alanine aminotransferase. 
eGFR, estimate glomerular filtration rate.  
 
 
Table 3. Baseline characteristics of people with type 2 diabetes by sex -specific quintiles of ferritin level in the ET2DS (n=821) 
 Q1 (n=162) 
 
Q2(n=164) 
 
Q3(n=167) 
 
Q4(n=164) 
 
Q5(n=164) 
 
P for trend 
Sex Male/Female n 84/78 85/79 85/82 84/80 84/80  
Ferritin levels range by sex 
(µg/L) 
      
Men (n=422) 7-36 37-74 75-123 124-198 199-1095  
Women (n=399) 5-20 21-38 39-69 70-119 120-605  
Variables       
Age (years) 69.9(65.5-72.7) 68.4(65.2-71.5) 68.6(65.2-72.5) 68.9(64.8-72.1) 69.7(65.5-72.8) 0.751 
Duration of diabetes (years) 9(5-14) 8(4-13) 8(5-11) 7(4-10) 5(3-10) <0.001 
Ferritin (µg/L) 17(11-25.2) 38(28-52) 75(55-98) 124(87-162.5) 246(177.5-338) <0.001 
Haemoglobin (g/dL) 13.4(12.5-14.5) 14.0(12.9-15.1) 14.1(13.2-15.1) 14.5(13.7-15.3) 14.6(13.6-15.5) <0.001 
Glucose mmol/L 6.2(5.0-8.0) 6.5(5.5-7.9) 6.3(5.3-7.5) 6.4(5.4-7.9) 6.7(5.8-8.2) 0.011 
HbA1C (%) 7.0(6.4-7.9) 7.0(6.5-7.7) 7.0(6.4-7.5) 7.0(6.4-7.7) 7.0(6.4-7.8) 0.525 
Fibrinogen (g/L) 3.5(3.1-4.0) 3.7(3.1-4.1) 3.6(3.0-4.21) 3.5(3.1-3.9) 3.5(3.1-4.0) 0.781 
CRP(mg/L) 1.5(0.7-3.0) 1.5(0.7-3.9) 1.8(0.8-4.6) 2.1(1.1-4.3) 2.2(1.0-4.5) <0.001 
GGT(U/L) 13(8-25.5) 14(9.0-23) 17(10-29) 17.5(10-31.7) 24.5(13-44.7) <0.001 
ALT(U/L) 29(24-34) 28(25-36) 31(25-36) 34(27.2-41) 36(28-47) <0.001 
AST(U/L) 27(22-32) 27(24-32) 28(24-33) 29(25-34.7) 33(27-41) <0.001 
Smoking [ever] n(%) 101(62.3) 89(54.3) 101(60.5) 103(62.8) 96(58.5) 0.935 
 
Alcohol consumption [ever] 
n(%) 
 
124(76.5) 
 
129(78.7) 
 
143(85.6) 
 
136(82.9) 
 
141(86) 
 
<0.001 
BMI (Kg/mts2)  30.8(27.6-34.4) 30.5(26.7-34.1) 30.2(27.3-33.8) 30.6(27.1-35.4) 30.7(27.9-34.0) 0.485 
SBP mmHg 132(120-142) 132(122-142) 130(122-140) 133(120-142) 134(124-144) 0.685 
DBP mmHg 68(60-74) 68(62-74) 70(62-76) 70(64-76) 70(64-78) 0.031 
HDL-cholesterol (mmol/L) 1.3(1.1-1.5) 1.3(1.1-1.5) 1.2(1.1-1.4) 1.2(1.0-1.4) 1.2(1.0-1.5) 0.006 
Total cholesterol (mmol/L) 4.1(3.7-4.6) 4.2(3.8-4.7) 4.1(3.6-4.8) 4.3(3.8-4.9) 4.2(3.7-4.8) 0.166 
Aspirin consumption n(%) 109(67.5) 111(67.7) 117(70.1) 111(67.7) 103(62.8) 0.208 
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eGFR, mL/min/1.73 m2 60(60-65.2) 60(60-71) 60(60-72) 60(60-73) 60(60-68.5) 0.757 
Oral hypoglycaemic drugs 
n(%) 
 
137(84) 
 
134(81.7) 
 
124(74.3) 
 
119(72.6) 
 
93(56.7) 
 
<0.001 
Antihypertensive drugs 
n(%) 
145(89.5) 139(84.8) 147(88) 136(82.9) 138(84.1) 0.147 
Lipid-lowering drugs n(%) 147(90.7) 132(80.5) 139(83.2) 137(83.5) 136(82.9) 0.168 
Insulin therapy n(%) 28(17.3) 25(15.2) 27(16.2) 21(12.8) 22(132.4) 0.250 
Liver disease n(%) 2(1.2) 0(0) 1(0.6) 6(3.7) 3(1.8) 0.102 
Outcomes at baseline n(%)       
CHD 59(36.4) 48(29.3) 50(29.9) 49(29.9) 44(26.8) 0.104 
CEVD 15(9.3) 15(9.1) 12(7.2) 19(11.6) 10(6.1) 0.576 
CVD (any cardiovascular 
event)  
67(41.4) 58(35.4) 52(31.1) 55(33.5) 53(32.3) 0.092 
Outcomes after follow-up       
Development of CHD  21(13) 12(7.3) 16(9.6) 20(12.2) 9(5.5) 0.107 
Development of CEVD  17(10.5) 7(4.3) 10(6.0) 9(5.5) 11(6.7) 0.306 
Development of CVD   
35(21.6) 
 
17(10.4) 
 
24(14.4) 
 
27(16.5) 
 
20(12.2) 
 
0.168 
Data are median (interquartile range) or n(%). P for trend across quintiles by Jonckheere-Terpstra Test (continbuous variables) and 2 tests 
(categorical variables). Q, quintile. CI, confidence interval. HDL-C, HDL cholesterol.. BMI, body mass index. GGT, gamma-glutamyl 
transpeptidase. ALT, Alanine aminotransferase. AST, Aspartate aminotransferase. CRP, C reactive protein. eGFR, estimate glomerular 
filtration rate. HbA1C, glycosylated haemoglobin. SBP, systolic blood pressure. DBP, diastolic blood pressure.  
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Table 4. Multivariate models* explaining prevalent cardiovascular disease in the ET2DS 
 OR 95%CI P value 
Ferritin 
(Z score of log-ferritin) 
 
0.81(0.68-0.96) 
 
0.018 
Ferritin (µg/L)   
Quintile 1 1.0(Reference)  
Quintile 2 0.80(0.48-1.32) 0.394 
Quintile 3 0.50(0.30-0.83) 0.008 
Quintile 4 0.65(0.39-1.09) 0.105 
Quintile 5 0.62(0.37-1.04) 0.073 
   
Sex (male as reference) 0.50(0.35-0.71) <0.001 
Fibrinogen µg/L 1.32(1.04-1.68) 0.018 
DBP mmHg 0.96(0.94-0.98) <0.001 
HDL-cholesterol (mmol/L) 0.30(0.18-0.52) <0.001 
Anti-hypertensive treatment 5.13(2.55-10.30) <0.001 
Glitazone treatment 0.50(0.31-0.78) 0.003 
Aspirin treatment  3.51(2.38-5.18) <0.001 
* Models on the basis of variables selected from a previous univariate analysis  (P<0.1) 
and which remained significant in the multivariate model after a backward elimination 
approach (P<0.05).  
The variables  tested in the univariate analysis were the following: age (at baseline), 
sex, duration of diabetes, use of specific anti-hyperglycaemic agents, treatment with 
insulin, lipid-lowering drugs, blood pressure-lowering drugs, smoking(ever/never), 
alcohol consumption (ever/never), body mass index (BMI), systolic blood pressure 
(SBP), diastolic blood pressure (DBP), HbA1c, fasting glucose, HDL-cholesterol, total 
cholesterol, C reactive protein (CRP), fibrinogen, liver enzymes, liver disease, estimated 
glomerular filtration rate (eGFR), haemoglobin levels, and aspirin treatment. Anaemia 
was alternatively tested instead of haemoglobin levels.  
** Value not added because the correspondent variable was not significant in the 
univariate analysis (P<0.1) or did not remain significant in the multivariate analysis 
(P<0.05).  
CI, confidence interval. CRP, C reactive protein. GGT, gamma-glutamyl transpeptidase. 
ALT, Alanine aminotransferase. eGFR, estimate glomerular filtration rate. DBP, diastolic 
blood pressure.  
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Table 5. Multivariate models* explaining incident cardiovascular disease in the ET2DS 
 Incident cardiovascular disease 
(n=821)  
Incident cardiovascular 
disease 
(n=536) –Excluding CVD 
cases at baseline 
 HR 95%CI P value HR 95%CI P value 
Ferritin 
(Z score of log-ferritin) 
 
0.86(0.72-1.04) 
 
0.136 
 
0.77(0.60-1.01) 
 
0.062 
Ferritin (µg/L)     
Quintile 1 1.0(Reference)  1.0(Reference)  
Quintile 2 0.50(0.28-0.90) 0.022 0.37(0.15-0.91) 0.031 
Quintile 3 0.58(0.34-0.98) 0.046 0.74(0.37-1.50) 0.415 
Quintile 4 0.76(0.45-1.28) 0.305 0.56(0.26-1.21) 0.145 
Quintile 5 0.46(0.26-0.83) 0.010 0.34(0.14-0.81) 0.016 
     
Age (years) 1.05(1.01-1.10) 0.010 1.08(1.01-1.15) 0.015 
Duration of diabetes (years) ** ** 4.38(1.77-10.8) 0.001 
CRP mg/L ** ** 1.82(1.05-3.14) 0.031 
GGT(U/L) 2.64(1.57-4.43) <0.001 2.83(1.44-5.56) 0.002 
ALT(U/L) 0.21(0.06-0.77) 0.019 ** ** 
HDL-cholesterol (mmol/L) 0.50(0.28-0.91) 0.024 ** ** 
eGFR, mL/min/1.73 m2 0.98(0.96-0.99) 0.007 ** ** 
Insulin therapy  1.87(1.22-2.87) 0.004 ** ** 
CVD at baseline  1.55(1.07-2.24) 0.019 *** *** 
* Models on the basis of variables selected from a previous univariate analysis  (P<0.1) and which 
remained significant in the multivariate model after a backward elimination approach (P<0.05). 
The variables  tested in the univariate analysis were the following: age (at baseline), sex, duration 
of diabetes, use of specific anti-hyperglycaemic agents, treatment with insulin, lipid-lowering drugs, 
blood pressure-lowering drugs, smoking(ever/never), alcohol consumption (ever/never), body 
mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), HbA1c, fasting 
glucose, HDL-cholesterol, total cholesterol, C reactive protein (CRP), fibrinogen, liver enzymes, 
liver disease, estimated glomerular filtration rate (eGFR), haemoglobin levels, and aspirin 
treatment. Anaemia was alternatively tested instead of haemoglobin levels. CVD at baseline was 
covariate for the total cohort (n=821). 
** Value not added because the variable was not significant in the univariate analysis (P<0.1) or 
did not remain significant in the multivariate analysis (P<0.05).  
*** This variable does not apply for this model.  
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CI, confidence interval. CRP, C reactive protein. GGT, gamma-glutamyl transpeptidase. ALT, 
Alanine aminotransferase. eGFR, estimate glomerular filtration rate. DBP, diastolic blood pressure. 
CVD, cardiovascular disease. The values of CRP, transaminases levels, glucose and total 
cholesterol were log-transformed for this analysis. 
 
 
 
 
 
 
 
